title: High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression.
abstract: Fragile X (fra(X)) males with a standardized IQ score of 70 or higher represent a high functioning (HF) or nonretarded fra(X) male group. This group, which does not include nonpenetrant males, has received little research attention to date. Of 221 fra(X) males who had been evaluated through The Children's Hospital in Denver since 1981 and had completed cognitive or developmental testing, 29 (13%) were high functioning by the above definition. We found that HF males on the whole had a lower cytogenetic score and were younger than retarded fra(X) males, but there was no difference between these two groups in the number of typical fra(X) physical manifestations present. FMR-1 DNA testing was performed on 134 fra(X) males and methylation status was determined for 51 of these. A greater percentage of HF males had a mosaic pattern or an incompletely methylated full mutation than did retarded males. A unique DNA pattern, an unmethylated fully expanded mutation, was discovered in 3 of the highest functioning fra(X) males. Protein studies performed on 2 of these males demonstrated the presence of FMR-1 protein, albeit at lower levels than normal. FMR-1 protein was not present in retarded fra(X) males. Significant FMR-1 protein expression may be responsible for higher cognitive functioning in the 2 males with unmethylated fully expanded mutations compared to retarded fra(X) males.
authors.affiliation: Child Development Unit, Children's Hospital, Denver, Colorado 80218.
authors.forename: R J
authors.initials: RJ
authors.lastname: Hagerman
authors.forename: C E
authors.initials: CE
authors.lastname: Hull
authors.forename: J F
authors.initials: JF
authors.lastname: Safanda
authors.forename: I
authors.initials: I
authors.lastname: Carpenter
authors.forename: L W
authors.initials: LW
authors.lastname: Staley
authors.forename: R A
authors.initials: RA
authors.lastname: O'Connor
authors.forename: C
authors.initials: C
authors.lastname: Seydel
authors.forename: M M
authors.initials: MM
authors.lastname: Mazzocco
authors.forename: K
authors.initials: K
authors.lastname: Snow
authors.forename: S N
authors.initials: SN
authors.lastname: Thibodeau
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D002648:Child; D002675:Child, Preschool; D004247:DNA / Q000378:metabolism; D004252:DNA Mutational Analysis; D051860:Fragile X Messenger Ribonucleoprotein 1; D005600:Fragile X Syndrome / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology*; D018628:Gene Dosage; D015870:Gene Expression; D006801:Humans; D007223:Infant; D007360:Intelligence / Q000235:genetics*; D008297:Male; D008745:Methylation; D008875:Middle Aged; D009030:Mosaicism; D009154:Mutation; D009419:Nerve Tissue Proteins / Q000096:biosynthesis*; D010375:Pedigree; D010641:Phenotype; D016601:RNA-Binding Proteins; D012044:Regression Analysis; D012091:Repetitive Sequences, Nucleic Acid
chemical_list: D004247:DNA; D051860:Fragile X Messenger Ribonucleoprotein 1; D009419:Nerve Tissue Proteins; D016601:RNA-Binding Proteins; C497683:FMR1 protein, human